Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
October 02, 2023 06:35 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia
September 18, 2023 08:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
September 11, 2023 06:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing
September 05, 2023 08:21 ET
|
Cellectar Biosciences
Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors Pivotal topline data in Waldenstrom’s macroglobulinemia...
Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
August 14, 2023 08:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization...
Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting
June 28, 2023 08:30 ET
|
Cellectar Biosciences
Interim data from 64 refractory multiple myeloma patients demonstrated an ORR of 28%, a CBR of 70%, and a DCR of 92% Demonstrated a 46% ORR in triple class refractory, 50% ORR in quad-class...
Cellectar Provides a Research and Development Program Summary
June 12, 2023 08:30 ET
|
Cellectar Biosciences
Waldenstrom’s macroglobulinemia pivotal trial top-line data now expected second half of 2023; pediatric high-grade glioma trial to initiate in Q3 Phospholipid drug conjugate platform validation with...
UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
May 04, 2023 09:22 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
May 04, 2023 08:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update
March 09, 2023 08:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization...